aTYR PHARMA (ATYR) Other financing activities (2015 - 2025)

aTYR PHARMA's (ATYR) quarterly Other financing activities came in at $17000.0 in Q2 2025, up 750.0% on a QoQ basis from $2000.0 in Q1 2025.

aTYR PHARMA (ATYR) Other financing activities (2015 - 2025) Analysis & Trends

aTYR PHARMA (ATYR) has 7 years of Other financing activities data on file, last reported at $17000.0 in Q2 2025.

Quarterly Other financing activities changed N/A year-over-year to $17000.0 in Q2 2025, while the trailing twelve-month figure through Mar 2026 was $17000.0 (up 750.0% YoY) and the FY2025 annual result came in at $19000.0, changed N/A from the prior year.
Other financing activities rose to $17000.0 in Q2 2025, from $2000.0 in the prior quarter.
In the past five years, Other financing activities ranged from a high of $58000.0 in Q3 2021 to a low of $1000.0 in Q1 2022.
A 3-year average of $16200.0 and a median of $3000.0 in 2021 frame the typical range for Other financing activities.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	aTYR PHARMA	49.54 Mn	-7.87 Mn	-

Download Data